

PLURISTEM THERAPEUTICS INC  
Form 8-K  
February 21, 2013

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 21, 2013

PLURISTEM THERAPEUTICS INC.  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction of  
incorporation)

001-31392  
(Commission file number)

98-0351734  
(I.R.S. Employer Identification  
Number)

MATAM Advanced Technology Park  
Building No. 5  
Haifa, Israel 31905  
31905  
(Address of principal executive offices)

Registrant's telephone number, including area code: 011 972 74 710 7171

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 8.01 Other Events.

On February 21, 2013, the registrant announced that the U.S. Food and Drug Administration (FDA) has granted the registrant's PLX cells orphan status designation for the treatment of aplastic anemia.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

Date: February 21, 2013

By: /s/ Yaky Yanay  
Yaky Yanay  
Chief Financial Officer